Drugs / gp100 antigen
gp100 antigen
Trials 32 · a red edge is where a trial was stopped
Also used as a comparator or background therapy in 5 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 14 trials | ||||||
| Phase 1 | NCT00559026 Comparator | Sep 2004 → Sep 2006 | melanoma | Italian National Institute of Health | Completed | No outcome recorded |
| Phase 1 | NCT00091338 Background | Aug 2004 → ? | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00025181 Background | Oct 2001 → Jan 2003 | cutaneous melanoma, ocular melanoma | University of Southern California | Completed | No outcome recorded |
| Phase 1 | NCT00003665 Background | Apr 1999 → Oct 2002 | cutaneous melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT00960752 Comparator | May 2010 → Jul 2020 | melanoma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 39 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | gp100 antigen | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00019175 ↗27 |
| Known as | gp100 | “The melanoma tumor antigen epitope peptides MART-1(26-35 (27L)), gp100(209-217 (210M)),and tyrosinase(368-376 (370D)) were emulsified with incomplete Freund's adjuvant and...” PMID 12684398 ↗ Apr 20039“Patients included in the study were assigned to two treatment arms either receiving anti-tumor vaccination with Melan-A and gp100 analog peptides alone (arm 1) or in...” NCT00559026 ↗ |
| Known as | Gp100 glycoprotein | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297963 ↗ |
| Known as | gp100:17-25 | “peptide immunization with gp100:209-217 (210M) or gp100:17-25 antigen” NCT00020358 ↗ |
| Known as | gp100:209-217 (210M) | “Define the antitumor activity of gp100:209-217 (210M), a melanoma peptide derived from gp100 mixed with Montanide ISA-51, in combination with high-dose interleukin-2 (IL-2)...” NCT00003568 ↗2“vaccination comprising modified gp100 peptide (gp100:209-217\[210M\]), Montanide ISA-51, and keyhole limpet hemocyanin” NCT00091143 ↗ “peptide immunization with gp100:209-217 (210M) or gp100:17-25 antigen” NCT00020358 ↗ |
| Known as | Melanocyte protein pmel | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297963 ↗ |
| Known as | Melanocyte protein pmel 17 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297963 ↗ |
| Known as | Melanoma-associated me20 antigen | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297963 ↗ |
| Known as | modified gp100 peptide | “vaccination comprising modified gp100 peptide (gp100:209-217\[210M\]), Montanide ISA-51, and keyhole limpet hemocyanin” NCT00091143 ↗ |
| Known as | Premelanosome protein | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297963 ↗ |
| Action | Deplete | “Vaccines made from peptides may make the body build an immune response to kill tumor cells.” NCT00089063 ↗ |
| Modality | Peptide | “mixture of synthetic melanoma peptides” NCT00003222 ↗ |
| Route | Subcutaneous | “vaccine comprising tyrosinase peptide and gp100 antigen emulsified in Montanide ISA-51 (ISA-51) alone subcutaneously (SQ) once a week” NCT00003274 ↗ |